Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 692

1.

Propylthiouracil attenuates monocrotaline-induced pulmonary arterial hypertension in rats.

Sun CK, Yuen CM, Kao YH, Chang LT, Chua S, Sheu JJ, Yen CH, Ko SF, Yip HK.

Circ J. 2009 Sep;73(9):1722-30. Epub 2009 Jul 15.

2.

Sildenafil limits monocrotaline-induced pulmonary hypertension in rats through suppression of pulmonary vascular remodeling.

Yen CH, Leu S, Lin YC, Kao YH, Chang LT, Chua S, Fu M, Wu CJ, Sun CK, Yip HK.

J Cardiovasc Pharmacol. 2010 Jun;55(6):574-84. doi: 10.1097/FJC.0b013e3181d9f5f4.

PMID:
20224427
3.

Allogenic stem cell therapy improves right ventricular function by improving lung pathology in rats with pulmonary hypertension.

Umar S, de Visser YP, Steendijk P, Schutte CI, Laghmani el H, Wagenaar GT, Bax WH, Mantikou E, Pijnappels DA, Atsma DE, Schalij MJ, van der Wall EE, van der Laarse A.

Am J Physiol Heart Circ Physiol. 2009 Nov;297(5):H1606-16. doi: 10.1152/ajpheart.00590.2009. Epub 2009 Sep 25.

4.

Amlodipine prevents monocrotaline-induced pulmonary arterial hypertension and prolongs survival in rats independent of blood pressure lowering.

Mawatari E, Hongo M, Sakai A, Terasawa F, Takahashi M, Yazaki Y, Kinoshita O, Ikeda U.

Clin Exp Pharmacol Physiol. 2007 Jul;34(7):594-600.

PMID:
17581214
5.

Autologous transplantation of bone marrow-derived endothelial progenitor cells attenuates monocrotaline-induced pulmonary arterial hypertension in rats.

Yip HK, Chang LT, Sun CK, Sheu JJ, Chiang CH, Youssef AA, Lee FY, Wu CJ, Fu M.

Crit Care Med. 2008 Mar;36(3):873-80. doi: 10.1097/CCM.0B013E318165B7EA.

PMID:
18431275
6.

Benefit of combined therapy with nicorandil and colchicine in preventing monocrotaline-induced rat pulmonary arterial hypertension.

Lee FY, Lu HI, Zhen YY, Leu S, Chen YL, Tsai TH, Chung SY, Chua S, Sheu JJ, Hsu SY, Chang HW, Sun CK, Yip HK.

Eur J Pharm Sci. 2013 Nov 20;50(3-4):372-84. doi: 10.1016/j.ejps.2013.08.004. Epub 2013 Aug 15.

PMID:
23954457
8.

Cilostazol therapy attenuates monocrotaline-induced pulmonary arterial hypertension in rat model.

Chang LT, Sun CK, Sheu JJ, Chiang CH, Youssef AA, Lee FY, Wu CJ, Yip HK.

Circ J. 2008 May;72(5):825-31.

9.

2-Methoxyestradiol mediates the protective effects of estradiol in monocrotaline-induced pulmonary hypertension.

Tofovic SP, Zhang X, Jackson EK, Dacic S, Petrusevska G.

Vascul Pharmacol. 2006 Dec;45(6):358-67. Epub 2006 Jun 8.

PMID:
16872912
10.

Attenuation of monocrotaline-induced pulmonary arterial hypertension in rats by rosuvastatin.

Li XL, Guan RJ, Li JJ.

J Cardiovasc Pharmacol. 2012 Aug;60(2):219-26. doi: 10.1097/FJC.0b013e31825cce63.

PMID:
22592772
11.

Early combined treatment with cilostazol and bone marrow-derived endothelial progenitor cells markedly attenuates pulmonary arterial hypertension in rats.

Sun CK, Lee FY, Sheu JJ, Yuen CM, Chua S, Chung SY, Chai HT, Chen YT, Kao YH, Chang LT, Yip HK.

J Pharmacol Exp Ther. 2009 Sep;330(3):718-26. doi: 10.1124/jpet.109.154328. Epub 2009 Jun 15.

12.

Specific inhibition of p38 mitogen-activated protein kinase with FR167653 attenuates vascular proliferation in monocrotaline-induced pulmonary hypertension in rats.

Lu J, Shimpo H, Shimamoto A, Chong AJ, Hampton CR, Spring DJ, Yada M, Takao M, Onoda K, Yada I, Pohlman TH, Verrier ED.

J Thorac Cardiovasc Surg. 2004 Dec;128(6):850-9.

14.

Estradiol metabolites attenuate monocrotaline-induced pulmonary hypertension in rats.

Tofovic SP, Salah EM, Mady HH, Jackson EK, Melhem MF.

J Cardiovasc Pharmacol. 2005 Oct;46(4):430-7.

PMID:
16160593
15.

Genistein, a phytoestrogen, attenuates monocrotaline-induced pulmonary hypertension.

Homma N, Morio Y, Takahashi H, Yamamoto A, Suzuki T, Sato K, Muramatsu M, Fukuchi Y.

Respiration. 2006;73(1):105-12. Epub 2005 Oct 1.

PMID:
16432296
16.

The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS.

Guerard P, Rakotoniaina Z, Goirand F, Rochette L, Dumas M, Lirussi F, Bardou M.

Naunyn Schmiedebergs Arch Pharmacol. 2006 Sep;373(6):401-14. Epub 2006 Aug 1.

PMID:
16896805
17.

Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.

Schäfer S, Ellinghaus P, Janssen W, Kramer F, Lustig K, Milting H, Kast R, Klein M.

Cardiovasc Res. 2009 Apr 1;82(1):30-9. doi: 10.1093/cvr/cvp002. Epub 2009 Jan 8.

18.

Alterations in pharmacological action of the right ventricle of monocrotaline-induced pulmonary hypertensive rats.

Daicho T, Yagi T, Takano S, Marunouchi T, Abe Y, Ohara M, Takeo S, Tanonaka K.

Biol Pharm Bull. 2009 Aug;32(8):1378-84.

19.

Apelin decreases myocardial injury and improves right ventricular function in monocrotaline-induced pulmonary hypertension.

Falcão-Pires I, Gonçalves N, Henriques-Coelho T, Moreira-Gonçalves D, Roncon-Albuquerque R Jr, Leite-Moreira AF.

Am J Physiol Heart Circ Physiol. 2009 Jun;296(6):H2007-14. doi: 10.1152/ajpheart.00089.2009. Epub 2009 Apr 3.

20.

The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin.

Rakotoniaina Z, Guerard P, Lirussi F, Goirand F, Rochette L, Dumas M, Bardou M.

Naunyn Schmiedebergs Arch Pharmacol. 2006 Dec;374(3):195-206. Epub 2006 Nov 11.

PMID:
17102939
Items per page

Supplemental Content

Write to the Help Desk